Galena Presents Data, Sarepta Updates Study: Healthcare Business Wrap

Galena Biopharma (NASDAQ:GALE), through a Friday press release, said that it presented data from the completed SN-33 Trial and final results from the Phase 1/2 trials of NeuVax” (nelipepimut-S or E75), at the 35^th Annual CTRC-AACR San Antonio Breast Cancer Symposium, which is being held December 4th through the 8th at the Henry B. Gonzalez Convention Center in San Antonio.

Sarepta Therapeutics (NASDAQ:SRPT) has reported updated data from Study 202, its open-label, Phase IIb extension evaluation of eteplirsen for the treatment of Duchenne muscular dystrophy. Patients treated with eteplirsen for 62 weeks and evaluable on ambulatory measures (modified Intent-to-Treat population) maintained a statistically significant clinical benefit on the primary clinical outcome measure, comprised of the 6-minute walk test , when compared to patients who received placebo for 24 weeks followed by 38 weeks of eteplirsen treatment.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Abiomed (NASDAQ:ABMD) announced Thursday that the FDA Circulatory System Devices Panel voted to retain Class III status for the temporary ventricular support devices within the non-roller type cardiopulmonary bypass blood pumps category, which includes Impella.

CombiMatrix Corporation (NASDAQ:CBMX) on Friday said in a press release that a pair of studies that have been published in a leading journal favor chromosomal microarray analysis over traditional karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirths. The evaluations were published in the current edition of the New England Journal of Medicine, representing the largest head-to-head studies comparing that analysis to traditional karyotyping.

Don’t Miss: Why Did Amarin’s Financing Announcement Spark a Sell-Off?